ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,591Medicare Part D Prescriptions Filled, Including Refills

Rank: 42 out of 103

$567K Total Retail Price of All Prescriptions

Rank: 30 out of 103

388 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Dakota
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 388 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

7% of this provider’s 388 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 8,434 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Dakota
LISINOPRIL 461 417 1 5
SIMVASTATIN 342 308 2 2
FUROSEMIDE 332 276 3 4
LEVOTHYROXINE SODIUM 327 277 4 1
AMLODIPINE BESYLATE 318 315 5 6
OMEPRAZOLE 300 261 6 3
WARFARIN SODIUM 261 218 7 7
METFORMIN HCL 241 178 8 13
PRAVASTATIN SODIUM 232 221 9 33
METOPROLOL TARTRATE 182 162 10 9
CRESTOR 160 140 11 27
HYDROCHLOROTHIAZIDE 151 134 12 16
ATENOLOL 125 115 13 14
DIGOXIN 125 120 13 25
METOPROLOL SUCCINATE 124 112 15 8
GLIMEPIRIDE 123 91 16 50
CARVEDILOL 121 102 17 20
ATORVASTATIN CALCIUM 114 105 18 18
LOSARTAN POTASSIUM 113 109 19 12
HYDROCODONE-ACETAMINOPHEN 112 106 S3 20 11
MELOXICAM 109 88 21 49
ZOLPIDEM TARTRATE 108 95 22 29
POTASSIUM CHLORIDE 107 87 23 10
CITALOPRAM HBR 98 75 24 15
ALENDRONATE SODIUM 95 87 25 19
ALLOPURINOL 95 91 25 26
TAMSULOSIN HCL 93 88 27 23
SERTRALINE HCL 91 79 28 21
ZETIA 85 66 29 66
GABAPENTIN 81 65 30 22
DIOVAN 81 76 30 40
SPIRIVA 76 74 32 64
FLUTICASONE PROPIONATE 75 72 33 35
TRAMADOL HCL 75 71 33 17
ADVAIR DISKUS 74 67 35 42
KLOR-CON 10 74 74 35 45
FAMOTIDINE 73 62 37 78
NEXIUM 71 64 38 43
LANTUS 67 67 39 39
IPRATROPIUM-ALBUTEROL 63 63 40 106
LEVEMIR FLEXPEN 61 53 41 158
CLOPIDOGREL 60 43 42 32
VENLAFAXINE HCL ER 53 44 43 110
PREDNISONE 53 50 43 24
RISPERIDONE 53 41 43 88
POLYETHYLENE GLYCOL 3350 52 48 46 31
AMLODIPINE BESYLATE-BENAZEPRIL 52 39 46 118
LISINOPRIL-HYDROCHLOROTHIAZIDE 51 46 48 48
ZOSTAVAX 51 47 48 181
FENOFIBRATE 50 13 50 58
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 4, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.